Nearly 20 years turning breakthrough technology into markets, launches, and multi-million-dollar brands — told the short way.
A multilingual strategy and commercialization executive who's spent nearly two decades building markets, launching products, and scaling growth across healthcare, MedTech, AI-enabled platforms, and B2B ventures. Andrea turns complex technology into clear positioning, go-to-market strategy, investor narratives, and revenue growth — the kind that shifts how an entire industry does business.
Andrea takes early-stage and acquired products from $0 to category leaders — turning small, overlooked businesses into the #1 selling product in their hospital category.
Builds commercial foundations that align clinical strategy, regulatory milestones, investor readiness, and physician adoption.
Works alongside founders, CEOs, and boards to lead commercialization from concept through FDA submission and launch.
Simplifies complex challenges, builds cross-functional teams and culture, and turns strategy into measurable adoption.
Global fluency built across a decade of international commercialization work spanning 50+ countries.
Leading Series A fundraising strategy and pitch development, building the clinical advisory board, and directing product management ahead of FDA submission — while defining market strategy and the go-to-market plan for Bloom's upstream portfolio.
A decade leading commercialization across cardiac, neuromodulation, and structural heart — from launching the first new pain therapy indication in 22 years to building the digital strategy for neuromodulation. Partnered with the diabetes team on a strategic collaboration, scaled a 25-person therapy awareness team, built a 100-physician KOL network, and educated 3,000+ physicians across 23 countries.
🏆 Marketing Excellence Award & RTG Star of ExcellenceGrew market share 9%, negotiating 7,500+ letters of commitment and securing 19 hospital IDN proposals.
Ranked a top-5 account executive company-wide across 170 hospital accounts, while helping cut packaging costs 40% through a Six Sigma initiative.
Andrea also serves on the Board of Trustees at the University of St. Catherine.
Whether you're preparing for FDA submission or scaling toward Series D, Andrea embeds as your commercial team — not another vendor.